Home › Funds › Parsonex Advisory Services, Inc. › VRTX
Parsonex Advisory Services, Inc. position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
Parsonex Advisory Services, Inc. reported holding 549 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$287K, representing 0.21% of its reported portfolio and ranking #48 among its reported holdings. Parsonex Advisory Services, Inc. has disclosed VRTX holdings in 5 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Parsonex Advisory Services, Inc.'s VRTX position evolved
Parsonex Advisory Services, Inc. first disclosed a stake in VRTX in Q2 2025 at 800 shares (US$356K). The position peaked in Q4 2025 at 1,031 shares, worth US$467K. Across 5 filings, Parsonex Advisory Services, Inc. increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 549 shares valued at US$287K. Notable position changes include a 27% increase in Q3 2025 (shares rose 16% over the following quarter), a 52% trim in Q1 2026 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 800 | $356.16K | New |
| Q3 2025 | 1.02K | $398.69K | Add |
| Q4 2025 | 1.03K | $467.41K | Add |
| Q1 2026 | 499 | $222.82K | Reduce |
| Q3 2026 | 549 | $287.02K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 25.97M sh · $13.58B · Q3 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 17.81M sh · $9.31B · Q3 2026
- Invesco Ltd 8.28M sh · $4.33B · Q3 2026
- Capital International Investors 5.06M sh · $2.65B · Q3 2026
- Franklin Resources 4.46M sh · $2.45B · Q3 2026
- LOOMIS SAYLES & CO L P 3.62M sh · $1.89B · Q3 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.56M sh · $1.34B · Q3 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on Parsonex Advisory Services, Inc.
FAQ
How long has Parsonex Advisory Services, Inc. held VRTX?
Parsonex Advisory Services, Inc. has disclosed VRTX holdings in 5 of the last 6 reported quarters, going back to Q2 2025.
What is Parsonex Advisory Services, Inc.'s current position in VRTX?
As of Q3 2026, Parsonex Advisory Services, Inc. holds 549 shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $287.02K, representing 0.21% of its reported portfolio and ranking #48.
Has Parsonex Advisory Services, Inc. been buying or selling VRTX?
In the latest 13F filing (Q3 2026), Parsonex Advisory Services, Inc. newly opened its position in VRTX. The position peaked in Q4 2025 at 1.03K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.